TABLE 2.

Summary of renin–angiotensin–aldosterone system (RAAS) blockade in cardiovascular disease states

ACEi and ARBs interrupt maladaptive pathophysiological responses to heightened activation of the RAAS

ARBs and ACEi mitigate the deleterious effects of unopposed AT1 receptor pathway activation, which in turn decreases inflammation, insulin resistance and lung injury

ACEi: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; AT₁: type 1 angiotensin II.